The specialists of Dalkhimpharm JSC are gaining the experience in manufacturing of new drugs under the import substitution program. The R&D portfolio of the plant includes now seven new medicines in the form of ampoules and suppositories, which it never produced before. Industrial scale production of these drugs is expected to start before the end of this year.
Currently, the plant is implementing the manufacturing of Pentoxifilin, a solution for injections that improves the blood circulation and its physiological properties, and acts as a vasoprotector, and Sodium thiosulfate, a powerful antioxidant that can cleanse the blood even in cases of cyanide, mercury, and hydrocyanic acid poisoning. After receiving the registration certificates for these products, the company will start producing pilot lots and, after obtaining the certificates of conformity, it will launch their industrial scale production. Another five new drugs (their names are kept secret) are next in the pipeline.
“Last year, we started to produce Mesaton, a solution for injections for patients with cardio-vascular diseases and hypotension, and Meloxicam, a suppository with anti-inflammatory, antipyretic, and analgesic properties. In the past, Mesaton was imported from Ukraine. But, with the imposition of sanctions against Russian, these supplies have stopped. Both medicines are included in the state list of vital and essential drugs and the list of drugs for import substitution. We couldn’t leave the patients, who need them, without treatment and started the production. Overall, our product range currently has 150 items, including 63 from the list of vital and essential drugs (it is particularly important that the prices for these drugs are controlled by the state),” said Irina Guseva, the Executive Director of Dalkhimpharm JSC.
Today, the plant employs 900 people. Although it operates in three shifts, the plant is ready to increase both the output and the range of its products, and make them available to consumers at reasonable prices.